Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial

Chemoradiotherapy (CRT) is the standard of care in locally advanced head and neck squamous cell carcinoma (LA-HNSCC), either post-operatively in patients at high-risk of recurrence [1,2] or as definitive CRT [3,4]. High-dose cisplatin, i.e. 100  mg/m2 every 3 weeks for 3 cycles (HD-Cis) has thus become the reference modality [4,5]. However, this treatment is associated with high toxicity (>80  % grade ≥ 3) [2,3], which compromises its administration, especially regarding the cumulative dose of cisplatin delivered concurrently with radiotherapy, as commonly 30–50 % of patients cannot receive the third cycle [1,5].

Source: Radiotherapy and Oncology - May 18, 2024 Category: Radiology Authors: Christian Borel, Xu-Shan Sun, Alexandre Coutte, Guillaume Bera, Christian Sire, Sylvie Zanetta, Marc Alfonsi, Guillaume Janoray, Thierry Chatellier, Muriel Garcia-Ramirez, Elisabeta Gherga, Yasser Hammoud, Micka ël Burgy, Nelly Etienne-Selloum, Adeline P Source Type: research